LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 379

Search options

  1. Book: Mycobacterium avium complex: improving gaps in diagnosis and management

    Daley, Charles / Winthrop, Kevin

    (The journal of infectious diseases ; volume 222, supplement 4 (15 September 2020))

    2020  

    Author's details editors: Charles Daley, MD, Kevin Winthrop, MD, MPH
    Series title The journal of infectious diseases ; volume 222, supplement 4 (15 September 2020)
    Collection
    Language English
    Size Seite S199-S211, Illustrationen, Diagramme
    Publisher Oxford University Press
    Publishing place Cary, NC
    Publishing country United States
    Document type Book
    HBZ-ID HT020617821
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Book: Infection and malignancy in rheumatic diseases

    Winthrop, Kevin L.

    (Rheumatic disease clinics of North America ; volume 43, number 1 (February 2017))

    2017  

    Author's details editors Kevin L. Winthrop, Leonard H. Calabrese
    Series title Rheumatic disease clinics of North America ; volume 43, number 1 (February 2017)
    Collection
    Language English
    Size xiv, 159 Seiten, Illustrationen
    Publisher Elsevier
    Publishing place Philadelphia, Pennsylvania
    Publishing country United States
    Document type Book
    HBZ-ID HT019267151
    ISBN 978-0-323-49675-9 ; 0-323-49675-X
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Article ; Online: What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases.

    Park, Jin Kyun / Lee, Eun Bong / Winthrop, Kevin L

    Annals of the rheumatic diseases

    2024  

    Abstract: Messenger RNA (mRNA) vaccines as a novel vaccine platform offer new tools to effectively combat both emerging and existing pathogens which were previously not possible. The 'plug and play' feature of mRNA vaccines enables swift design and production of ... ...

    Abstract Messenger RNA (mRNA) vaccines as a novel vaccine platform offer new tools to effectively combat both emerging and existing pathogens which were previously not possible. The 'plug and play' feature of mRNA vaccines enables swift design and production of vaccines targeting complex antigens and rapid incorporation of new vaccine constituents as needed. This feature makes them likely to be adopted for widespread clinical use in the future.Currently approved mRNA vaccines include only those against SARS-CoV-2 virus. These vaccines demonstrate robust immunogenicity and offer substantial protection against severe disease. Numerous mRNA vaccines against viral pathogens are in the early to late phase of development. Several mRNA vaccines for influenza are tested in clinical trials, with some already in phase 3 studies. Other vaccines in the early and late phases of development include those targeting
    Language English
    Publishing date 2024-02-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/ard-2024-225492
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Who Needs a Corona?

    Winthrop, Kevin L

    Arthritis & rheumatology (Hoboken, N.J.)

    2020  Volume 72, Issue 6, Page(s) 874–876

    MeSH term(s) Antirheumatic Agents/adverse effects ; Betacoronavirus ; Biological Products/adverse effects ; COVID-19 ; Coronavirus Infections/mortality ; Coronavirus Infections/transmission ; Coronavirus Infections/virology ; Humans ; Pandemics ; Pneumonia, Viral/mortality ; Pneumonia, Viral/transmission ; Pneumonia, Viral/virology ; Rheumatic Diseases/drug therapy ; Rheumatic Diseases/virology ; Risk Factors ; SARS-CoV-2
    Chemical Substances Antirheumatic Agents ; Biological Products
    Keywords covid19
    Language English
    Publishing date 2020-04-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.41260
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: In the shadow of antibodies: how T cells defend against COVID-19.

    Pisetsky, David S / Winthrop, Kevin L

    Annals of the rheumatic diseases

    2022  Volume 81, Issue 6, Page(s) 757–759

    MeSH term(s) Antibodies, Viral ; COVID-19 ; Humans ; Lymphocyte Count ; SARS-CoV-2 ; T-Lymphocytes
    Chemical Substances Antibodies, Viral
    Language English
    Publishing date 2022-04-07
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2021-221952
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Nontuberculous Mycobacteria: Diagnosis and Therapy.

    Varley, Cara D / Winthrop, Kevin L

    Clinics in chest medicine

    2022  Volume 43, Issue 1, Page(s) 89–98

    Abstract: Patients with bronchiectasis are at high risk for nontuberculous mycobacteria (NTM) disease and suspicion should be high in the setting of worsening respiratory symptoms and disease progression on imaging. Meeting the case definition for NTM disease does ...

    Abstract Patients with bronchiectasis are at high risk for nontuberculous mycobacteria (NTM) disease and suspicion should be high in the setting of worsening respiratory symptoms and disease progression on imaging. Meeting the case definition for NTM disease does not equal a decision to treat; risk and benefits of therapy should be discussed with patients. When treatment is initiated, a multidrug regimen should be used and selected based on susceptibility testing from a reliable laboratory. Monotherapy or macrolide-fluoroquinolone dual therapy should never be used. After discontinuation of therapy, ongoing mycobacterial sputum culture surveillance is needed, as infection relapse is common.
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Disease Progression ; Humans ; Laboratories ; Mycobacterium Infections, Nontuberculous/diagnosis ; Mycobacterium Infections, Nontuberculous/drug therapy ; Nontuberculous Mycobacteria
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2022-03-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 447455-7
    ISSN 1557-8216 ; 0272-5231
    ISSN (online) 1557-8216
    ISSN 0272-5231
    DOI 10.1016/j.ccm.2021.11.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Oral surveillance and JAK inhibitor safety: the theory of relativity.

    Winthrop, Kevin L / Cohen, Stanley B

    Nature reviews. Rheumatology

    2022  Volume 18, Issue 5, Page(s) 301–304

    Abstract: The published results of the post-marketing ORAL Surveillance study, which compared the Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with rheumatoid arthritis who have cardiovascular risk factors, have led to changes ... ...

    Abstract The published results of the post-marketing ORAL Surveillance study, which compared the Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with rheumatoid arthritis who have cardiovascular risk factors, have led to changes in the recommendations for the use of JAK inhibitors. Although new safety signals have emerged for tofacitinib, namely malignancy and cardiovascular disease, it should be noted that these signals are relative to those seen with TNF blockers. The new data further raise our intrigue that venous thromboembolism might be a true risk related to JAK inhibition. Reassuringly, the totality of the findings from this newly published study and the other data collected to date suggest that JAK inhibitors can be used safely at approved doses by many patients with rheumatoid arthritis.
    MeSH term(s) Aged ; Arthritis, Rheumatoid/drug therapy ; Humans ; Janus Kinase Inhibitors/adverse effects ; Pyrroles/adverse effects ; Tumor Necrosis Factor Inhibitors
    Chemical Substances Janus Kinase Inhibitors ; Pyrroles ; Tumor Necrosis Factor Inhibitors
    Language English
    Publishing date 2022-03-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/s41584-022-00767-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: You Gotta Make Me See, What Does It Mean to Have an MIC?

    Griffith, David E / Winthrop, Kevin L

    Chest

    2021  Volume 159, Issue 2, Page(s) 462–464

    Language English
    Publishing date 2021-02-05
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1016/j.chest.2020.11.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Rheumatology and COVID-19 at 1 year: facing the unknowns.

    Calabrese, Leonard / Winthrop, Kevin L

    Annals of the rheumatic diseases

    2021  Volume 80, Issue 6, Page(s) 679–681

    MeSH term(s) COVID-19 ; Humans ; Rheumatic Diseases/epidemiology ; Rheumatology ; SARS-CoV-2
    Language English
    Publishing date 2021-03-03
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2021-219957
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top